Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role?

Lancet Diabetes Endocrinol. 2020 Nov;8(11):870-871. doi: 10.1016/S2213-8587(20)30301-6. Epub 2020 Sep 21.
No abstract available

Publication types

  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetic Nephropathies* / drug therapy
  • Glucagon-Like Peptide-1 Receptor
  • Glucagon-Like Peptides
  • Humans
  • Hypoglycemic Agents / therapeutic use

Substances

  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • semaglutide
  • Glucagon-Like Peptides